Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp has reported promising results for its MDNA11 immunotherapy treatment in advanced solid tumors, with a pancreatic cancer patient achieving complete remission for over 104 weeks and a melanoma patient also showing sustained regression of all target lesions. The Phase 1/2 ABILITY-1 study noted that MDNA11 was well-tolerated and produced significant increases in immune cell markers associated with cancer response, without any reported dose limiting toxicities. These findings were presented at the 10th Annual Oncology Innovation Forum, indicating potential for MDNA11 as a leading next-generation IL-2 super-agonist for treating advanced solid tumors.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
